11 Result(s)
within
Samantha C. Burnham
-
Article
Open AccessCombining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
Maximizing the efficiency to screen amyloid-positive individuals in asymptomatic and non-demented aged population using blood-based biomarkers is essential for future success of clinical trials in the early st...
-
Article
Open AccessNovel Alzheimer’s disease genes and epistasis identified using machine learning GWAS platform
Alzheimer’s disease (AD) is a complex genetic disease, and variants identified through genome-wide association studies (GWAS) explain only part of its heritability. Epistasis has been proposed as a major contr...
-
Article
Open AccessComprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume
The concept of age acceleration, the difference between biological age and chronological age, is of growing interest, particularly with respect to age-related disorders, such as Alzheimer’s Disease (AD). Whils...
-
Article
Open AccessMesial temporal tau in amyloid-β-negative cognitively normal older persons
Tau deposition in the mesial temporal lobe (MTL) in the absence of amyloid-β (Aβ−) occurs with aging. The tau PET tracer 18F-MK6240 has low non-specific background binding so is well suited to exploration of earl...
-
Article
Open AccessUsing imputation to provide harmonized longitudinal measures of cognition across AIBL and ADNI
To improve understanding of Alzheimer’s disease, large observational studies are needed to increase power for more nuanced analyses. Combining data across existing observational studies represents one solution...
-
Article
Open AccessElecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging
β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer’s disease (AD). However, numerous researc...
-
Article
Open AccessApplication of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer’s Disease using Cerebrospinal Fluid Biomarkers in the AIBL Study
The National Institute on Aging and Alzheimer’s Association (NIA-AA) have proposed a new Research Framework: Towards a biological definition of Alzheimer’s disease, which uses a three-biomarker construct: Aß-a...
-
Article
Open AccessBlood-based molecular biomarkers for Alzheimer’s disease
A major barrier to the effective conduct of clinical trials of new drug candidates against Alzheimer’s disease (AD) and to identifying patients for receiving future disease-modifying treatments is the limited ...
-
Article
Author Correction: Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
In Figure 1 of this article as originally published, the chemical structure at bottom right was incorrectly labelled 18F-PM-PBB3. The text label has been corrected to 18F-PBB3 in the PDF and HTML versions of the ...
-
Article
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
The clinical phenotypes of patients with proteinopathies do not always enable identification of the underlying cause of the disorder, especially in early disea...
-
Article
Open AccessKIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden
A single nucleotide polymorphism, rs17070145, in the KIdney and BRAin expressed protein (KIBRA) gene has been associated with cognition and hippocampal volume in cognitively normal (CN) individuals. However, the ...
